Exosome

Phase 1Cell therapy

PParacrine Therapeutics Dermatology Pte. Ltd.

Exosome is one of 65 biologic programs targeting Acute Liver Failure. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Liver FailureActive, not recruiting

OsteoarthritisActive, not recruiting

Ischemic StrokeActive, not recruiting

Acute Liver FailurePhase 1

Active, not recruiting

OsteoarthritisPreclinical

Active, not recruiting

Ischemic StrokePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 2

Toradol

Roche

Preclinical

1 3

Cataflam

Platelet Rich Plasma

25 5

Enbrel

IImmunex

Preclinical

2 6

Paracetamol

GSK

Preclinical

4 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Lunesta

Akero Therapeutics

Preclinical

1 9

Naproxen Sodium

Bayer

Preclinical

1 10

Ansaid

PPharmacia and Upjohn

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Osteoarthritis

NCT06466850

Q3 2027

Phase 1Active, not recruiting

Acute Liver Failure

NCT07409259

Clinical

Trials by Indication[1]

Acute Liver Failure1 trial

PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure

Active, not recruiting·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 1·NCT07409259·20 enrolled

Osteoarthritis1 trial

Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients

Recruiting·IIsfahan University of Medical Sciences·N/A·NCT06466850·20 enrolled

Ischemic stroke1 trial

Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke

Unknown status·IIsfahan University of Medical Sciences·Phase 1/2·NCT03384433·5 enrolled

Unspecified1 trial

Safety and Tolerability Study of MSC Exosome Ointment

Completed·PParacrine Therapeutics Dermatology Pte. Ltd.·Phase 1·NCT05523011·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Exosome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Exosome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Exosome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Paracrine Therapeutics Dermatology Pte. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: PParacrine Therapeutics Dermatology Pte. Ltd.

Exosome

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Trials by Indication[1]

Acute Liver Failure1 trial

Osteoarthritis1 trial

Ischemic stroke1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News